Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hayashi, Masamichi ^a   Nomoto, Shuji ^a   Hishida, Mitsuhiro ^a   Inokawa, Yoshikuni ^a   Kanda, Mitsuro ^a   Okamura, Yukiyasu ^a   Nishikawa, Yoko ^a   Tanaka, Chie ^a   Kobayashi, Daisuke ^a   Yamada, Suguru ^a   Nakayama, Goro ^a   Fujii, Tsutomu ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Takeda, Shin ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen type 1 alpha 1; Hepatocellular carcinoma; Methylation

Indexed keywords

MESSENGER RNA; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; DECITABINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL ARTICLE; COLLAGEN TYPE 1 ALPHA 1 GENE; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; MARKER GENE; METHYLATION; OVERALL SURVIVAL; PRIMARY TUMOR; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; ADULT; CANCER PROGNOSIS; CHROMOSOME DELETION; COL1A1 GENE; DNA METHYLATION; GENE; GENE EXPRESSION; SEQUENCE ANALYSIS;

AGED; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLLAGEN TYPE I; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; SURVIVAL RATE;

EID: 84896720463     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-108     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127. 10.1056/NEJMra1001683, 21992124.
3. Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol 2011, 41:447-454. 10.1093/jjco/hyr016, 21411469.
4. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, Curley SA, Laurent A, Poon RT, Belghiti J, Nagorney DM, Aloia TA, International Cooperative Study Group on Hepatocellular Carcinoma Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013, 17:66-77. discussion 77, 10.1007/s11605-012-2005-4, 3880185, 22948836, International Cooperative Study Group on Hepatocellular Carcinoma.
5. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 2009, 35:477-483.
6. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S, Nakao A. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010, 17:923-932. 10.1245/s10434-009-0790-0, 19898900.
7. Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett 2010, 289:170-177. 10.1016/j.canlet.2009.08.013, 19733004.
8. Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 2011, 50:571-579. 10.1002/mc.20735, 21268132.
9. Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, Sugimoto H, Takeda S, Nakao A. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol 2011, 18:572-579. 10.1245/s10434-010-1273-z, 20734148.
10. Hayashi M, Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol 2012, 105:381-386. 10.1002/jso.22135, 22052684.
11. Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 2010, 25:1152-1159. 10.3346/jkms.2010.25.8.1152, 2908783, 20676325.
12. Okamura Y, Nomoto S, Hayashi M, Hishida M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y, Nakao A. Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Lett 2011, 312:150-157. 10.1016/j.canlet.2011.07.028, 21943823.
13. Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Fujiwara M, Takeda S, Kodera Y. Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol 2013, 43:88-94.
14. Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, Kodera Y. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res 2013, 32:65. 10.1186/1756-9966-32-65, 3847884, 24034596.
15. Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, Fujii T, Nakayama G, Yamada S, Tanaka C, Kobayashi D, Kodera Y. Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther 2013, 6:1417-1424. 3797647, 24143113.
16. Xia XY, Cui YX, Huang YF, Pan LJ, Yang B, Wang HY, Li XJ, Shi YC, Lu HY, Zhou YC. A novel RNA-splicing mutation in COL1A1 gene causing osteogenesis imperfecta type I in a Chinese family. Clin Chim Acta 2008, 398:148-151. 10.1016/j.cca.2008.07.030, 18755172.
17. Koilan S, Hamilton D, Baburyan N, Padala MK, Weber KT, Guntaka RV. Prevention of liver fibrosis by triple helix-forming oligodeoxyribonucleotides targeted to the promoter region of type I collagen gene. Oligonucleotides 2010, 20:231-237. 10.1089/oli.2010.0244, 2957239, 20818932.
18. Cicinnati VR, Shen Q, Sotiropoulos GC, Radtke A, Gerken G, Beckebaum S. Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR. BMC Cancer 2008, 8:350. 10.1186/1471-2407-8-350, 2607287, 19036168.
19. Ibanez De Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006, 66:5021-5028. 10.1158/0008-5472.CAN-05-3365, 16707423.
20. Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, Nishie A, Hirakawa M, Ushijima Y, Okamoto D, Taketomi A, Honda H. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009, 250:435-443. 10.1148/radiol.2501071702, 19095782.
21. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001, 16:777-781. 10.1046/j.1440-1746.2001.02515.x, 11446886.
22. Attallah AM, Mosa TE, Omran MM, Abo-Zeid MM, El-Dosoky I, Shaker YM. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007, 28:155-168. 10.1080/15321810701212088, 17424834.
23. Kao YH, Chen CL, Jawan B, Chung YH, Sun CK, Kuo SM, Hu TH, Lin YC, Chan HH, Cheng KH, Wu DC, Goto S, Cheng YF, Chao D, Tai MH. Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J Hepatol 2010, 52:96-105. 10.1016/j.jhep.2009.10.002, 19913322.
24. Lin ZY, Chuang WL. Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother 2012, 66:454-458.
25. Sengupta P, Xu Y, Wang L, Widom R, Smith BD. Collagen alpha1(I) gene (COL1A1) is repressed by RFX family. J Biol Chem 2005, 280:21004-21014. 10.1074/jbc.M413191200, 1382295, 15788405.
26. Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 2013, 42:912-920.
27. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neurol Oncol 2008, 10:981-994.
28. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009, 19:1462-1470. 10.1101/gr.091447.109, 2720187, 19491193.
29. Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 2011, 6:e26121. 10.1371/journal.pone.0026121, 3197591, 22028813.
30. Misawa K, Kanazawa T, Misawa Y, Imai A, Endo S, Hakamada K, Mineta H. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Cancer Biomark 2011, 10:135-144.
31. Mori K, Enokida H, Kagara I, Kawakami K, Chiyomaru T, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M. CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int J Oncol 2009, 34:1593-1602.
32. Dahlman T, Lammerts E, Bergström D, Franzén A, Westermark K, Heldin NE, Rubin K. Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicity. Int J Cancer 2002, 98:186-192. 10.1002/ijc.10181, 11857406.
33. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45. 10.1016/S0092-8674(03)00513-0, 12859896.
34. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31:4567-4576. 10.1038/onc.2011.611, 22249249.
35. Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology 2013, 84:158-165. 10.1159/000341366, 23296063.
36. Rajasekhar VK, Dalerba P, Passegué E, Lagasse E, Najbauer J. The 5th International Society for Stem Cell Research (ISSCR) Annual Meeting, June 2007. Stem Cells 2008, 26:292-298. 10.1634/stemcells.2007-0647, 17962698.
37. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803. 10.1002/cncr.21792, 16532500.
38. Herranz M, Martín-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez V, Esteller M. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 2006, 107:1174-1177.
39. Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer: progress to date. Drugs 2011, 71:2391-2403. 10.2165/11596690-000000000-00000, 22141383.
40. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70. 10.1002/hep.23660, 20578129.
41. Saito Y, Hibino S, Saito H. Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Res in press.